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Abstract: Identifying cancer drivers and actionable mutations is critical for precision oncology.
In epithelial ovarian cancer (EOC) the majority of mutations lack biological or clinical validation.
We fully characterized 43 lines of Patient-Derived Xenografts (PDXs) and performed copy
number analysis and whole exome sequencing of 12 lines derived from naïve, high grade EOCs.
Pyrosequencing allowed quantifying mutations in the source tumours. Drug response was assayed
on PDX Derived Tumour Cells (PDTCs) and in vivo on PDXs. We identified a PIK3R1W624R variant in
PDXs from a high grade serous EOC. Allele frequencies of PIK3R1W624R in all the passaged PDXs and
in samples of the source tumour suggested that it was truncal and thus possibly a driver mutation.
After inconclusive results in silico analyses, PDTCs and PDXs allowed the showing actionability
of PIK3R1W624R and addiction of PIK3R1W624R carrying cells to inhibitors of the PI3K/AKT/mTOR
pathway. It is noteworthy that PIK3R1 encodes the p85α regulatory subunit of PI3K, that is very
rarely mutated in EOC. The PIK3R1W624R mutation is located in the cSH2 domain of the p85α that has
never been involved in oncogenesis. These data show that patient-derived models are irreplaceable
in their role of unveiling unpredicted driver and actionable variants in advanced ovarian cancer.
Keywords: ovarian cancer; PI3K; PIK3R1; Patient-Derived xenografts; PDX derived tumour cells
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1. Introduction
Epithelial Ovarian Cancer (EOC) is a heterogeneous disease with five major histologic types [1].
The most frequent is high grade serous EOC (HGS-EOC), characterized by disruption of TP53 [2].
The majority of patients with HGS-EOC present with advanced stage disease and there has been
little improvement in overall survival with standard treatment, which has not changed over the past
20 years and relies on cytoreductive surgery and platinum-based combination chemotherapy [3].
Maintenance therapy with inhibitors of the Poly (ADP-ribose) polymerase (PARP) now offers significant
survival advantages for patients with BRCA1 and BRCA2 mutations [4,5], but targeted therapy for
other HGS-EOC patients is much less developed compared to other solid tumours. In melanoma and
non-small cell lung carcinomas, specific genetic alterations have been identified as key oncogenic
drivers, i.e., as mutations able to confer a selective advantage to a cell, through either increasing its
survival or proliferation and, thus, able to cause clonal expansion of the carrier cell. These findings
have led to the development of therapies targeting these mutations, which has provided demonstrable
clinical benefit [6]. Thus, a number of these mutations have also been defined as “actionable”, not only
because their functional outcome makes carrier cells responsive to a targeted therapy, but also thanks
to the availability of a specific targeted drug.
In ovarian cancer, a handful of aberrations in cancer genes have been found at high frequency,
but many more cancer-related genes are found mutated at a very low frequency (≈1%) [7,8].
This so-called “long-tail” of candidate driver mutations [9] is still incompletely characterized not only
in ovarian cancer but also across other human cancers [10]. Many of these mutations are not even well
characterized oncogenic drivers [7,8] and evidence of the potential clinical impact is lacking.
Thus, the goal of this study is to identify driver and therapeutically actionable molecular
alterations in ovarian cancer. Primarily, with this purpose in mind, we [11] and other groups [12–18]
have developed platforms of Patient-Derived Xenografts (PDXs) of EOC that can recapitulate the
tumour biology and clinical responses observed in donor patients. PDXs provide the most conclusive
tool to validate low frequency mutations as biomarkers for targeted therapy, as evidenced by the use
of colorectal cancer PDX models to predict successful clinical trials [19].
Using PDX and PDX Derived Tumour Cells (PDTC), we provide here the identification and the
detailed functional and therapeutic validation of aPIK3R1W624R mutation found in HGS-EOC. In HGS-EOC
point, mutations of genes encoding proteins of the PI3K-AKT-mTOR signalling pathway are very rare,
whereas this pathway is very frequently affected by large genetic aberrations. The importance of this
pathway in this and other cancer histotypes has prompted the clinical development of >40 different
inhibitors [20]. However, we show here that although rare, the PIK3R1W624R is likely important, because it
is identified as a truncal mutation in both the PDX line and source tumour. Thus, the PDX model has been
instrumental in propelling the analysis, precisely because the genomic evolution of the source tumour
grown in the immunodeficient animal model [21] did not counter-select this mutation. Moreover, we
show here that the PDX model has been invaluable for functional validation, as it allowed overcoming
questionable assays in test tubes or in unrelated cell types.
2. Materials and Methods
2.1. Cell Lines
The OVCAR-8 (NCI-DTP Cat# OVCAR-8) were obtained from the NCI-DCTD repository.
The A2780 (NCI-DTP Cat# A2780) ovarian carcinoma cells lines and the LNCaP prostate carcinoma cell
line (CLS Cat# 300265/p761_LNCaP) were purchased from American Type Culture Collection (ATCC).
Cell cultures were maintained following the protocols suggested by the providers.
2.2. Patient-Derived Xenograft (PDX) Platform
Between 2012 and 2016, a collection of 167 separate clinical samples of epithelial ovarian cancers
was undertaken, with the understanding and written consent of each subject before they participated in
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the study, and according to the PROFILING Protocol, and it also conformed to the standards set by the
Declaration of Helsinki, and was approved by the Regione Piemonte Ethical Committee (approval number
5141 on 9/3/2011), and then by the IRCCS Ethical Committee (approval number 192/2016 on 19/7/2016).
Samples have been implanted intra-peritoneum and subcutaneously in the right flank of severely
immunocompromised NOD/Shi-scid/IL-2R γnull mice and subsequently propagated subcutaneously,
based on our and other authors’ data showing that the continued development of the PDX model
subcutis was suitable [11,12]. Sample quality was assessed by the pathologists. A total of 65 PDX
lines successfully grew (thus with an approximate take of 40%) and were propagated for at least three
passages. Table S1 shows the full characterization of tumours and a quality assurance of 43/65 PDX
lines, carried out in accordance with Meehan et al. [22] within the first three passages of PDX lines,
which resulted in loss of human stroma. For treatment, animals were randomized using the Laboratory
Assistant Suite [23]. Animal treatment was initiated when mean xenograft volume was approximately
100 mm3. Buparlisib diluted in N-Methyl-2-pyrrolidone and PEG 10/90 v/v was administered by oral
gavage every day 5 days/week for 3 weeks. Buparlisib was administered at the dose of 20 mg/kg,
that was reported to be effective in diverse PDX models [24]. Treatment with buparlisib at doses
>30 mg/kg resulted in mouse toxicity. Control animals were treated with vehicle alone. All animal
procedures were approved by the local Ethical Commission and by the Italian Ministry of Health in
accordance with EU Directive 2010/63/EU for animal experiments; a first authorization was obtained on
12/7/2012 and, following subsequent regulations, approved again on 14/01/2016 (no. 16/2016-PR) and
extended for two additional years on 17/9/2018. All animal procedures comply with the “3R” principles.
Additional methodological details of animal experimentation are reported in Supplementary Methods
Part 1. The completed ARRIVE guideline checklist for reporting experiments using live animals is
attached as Supplementary Methods Part 2.
2.3. TMAs and IHC
Tissue Microarray (TMA) preparations and staining were carried out as described by
Sapino et al. [25] TMA slides for the characterization of the PDX lines were stained with the Ventana
automated immunostainer (BenchMark AutoStainer, Ventana Medical Systems, Tucson, AZ, USA)
using the following antibodies by Ventana Medical Systems: anti-WT1 Cat# 760-4397, anti-p53 Cat#
790-2912, anti-EPCAM Cat# 760-4383, anti-Cytokeratin 7 Cat# 790-4462 and anti-CD20 Cat# 760-2531,
the latter to rule out the growth of lymphoma, which occurred in 10–20% of cases, as also reported by
others [26]. Immunohistochemical detection of S6 and P-S6 in TMA slides of PDXs was carried out using
rabbit monoclonal antibodies (Cell Signalling Technology; Denvers, MA, USA) Cat# 2217 and Cat# 4858,
respectively, and anti-rabbit Ig (K4003) and EnVision system purchased from Dako (Agilent, Santa Clara,
CA, USA). The immunohistochemical detection of Ki67 and P-S6 in sections of PDXs was carried
out using mouse monoclonal (Dako clone MIB-1) and rabbit monoclonal antibodies (Cell Signalling
Technology Cat# 4858) respectively, anti-mouse or anti-rabbit Ig (K4001 and K4003, respectively) and
EnVision system purchased from Dako (Agilent, Santa Clara, CA, USA). Quantification of P-S6 and
Ki67 positive cells was carried out using the Colour Deconvolution plug-in in ImageJ in 20–30 and
10–15 separated fields, respectively, of each PDX.
2.4. PDX Derived Tumour Cell (PDTC) Preparation
PDX samples have been chopped and digested with a Human Tumour Dissociation Kit (Miltenyi
Biotec, Bergisch Gladbach, Germany) according to the manufacturer protocol. Human cells were
isolated using a Mouse Cell Depletion Kit (Miltenyi Biotec). Cells were plated, and after 24–48 h treated
with a drug in 96-multiwell plates.
2.5. Viability and Cytotoxicity Assays
A CellTiter-Glo® assay was used to evaluate the viability of PDTCs and cell lines after 72 h treatment
with drugs, according to the manufacturer’s protocol (Promega, Madison, WI, USA). Drugs were purchased
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from Selleck Chemicals (Houston, TX, USA). GR values have been calculated for each concentration as
reported in Hafner et al. [27] and plotted using a GraphPad Prism version 7.02 (San Diego, CA, USA).
A c ytotoxicity assay was carried out as follows. Seventy-two hours after treatment, cells in
96-well plates were fixed with 2% paraformaldehyde in PBS for 40 min, washed twice in PBS and
stained with 10% crystal violet in 20% methanol for 40 min. Plates were washed extensively and lysed
in 10% acetic acid. The absorbance was measured at 595 nm using a microplate reader (BioTek Synergy
HTX, Winooski, VT, USA).
2.6. Western Blot Analysis
PDTCs were treated for 24 h with the indicated drug or the vehicle 24 h after plating. From PDTCs
and PDX samples, proteins were extracted in ice cold elution buffer (TrisHCl pH 7.4, containing
EDTA, 1% Triton X-100, 10% glycerol and protease and phosphatase inhibitors). Proteins of snap
frozen PDXs have been extracted as above after GentleMacs (Miltenyi Biotec) digestion. Western blot
(WB) analysis was carried using the following antibodies: rabbit polyclonal anti-AKT (Cell Signalling
Technology Cat# 9272), rabbit monoclonal Phospho(Ser473)-AKT (Cell Signaling Technology Cat# 4060)
and polyclonal goat anti-vinculin (N-19) (Santa Cruz Biotechnology Cat# sc-7649). Labelled secondary
antibodies have been revealed with ECL (Thermo Fisher Scientific, Waltham, MA, USA) using the
ChemiDoc Touch Imaging System (BioRad, Hercules, CA, USA).
2.7. Crystal Structure Analysis
The position of W624 residue in the structure of human p85α encoded by PIK3R1 was predicted
through sequence alignments and structure superimposition. Sequence alignments and domain
assignment were performed using PSI-Blast (NCBI BLAST), whereas structure superimposition was
performed using UCSF Chimera.
2.8. WES and CNA Analysis
Exome library preparation was performed using the Nextera Rapid Capture Enrichment kit from
Illumina. Genomic DNAs were quantified using the Qubit system (Invitrogen, Carlsbad, CA, USA)
and 50 ng were used as input material for library preparation. Pools of 12-plex libraries (500 ng each
library) were hybridized with capture probes (coding exomes oligos) twice: a first hybridization step
for 2 h and a second for 18 h. After elution and clean up, enriched DNA libraries were amplified
with 10-cycle PCR. The products were purified, loaded on a bioanalyser using DNA 1000 chip for
quality control and quantified with Qubit. Samples were sequenced using the NextSeq 500 platform
(Illumina, San Diego, CA, USA) as paired 150 bp reads, using the NextSeq 500/550 High Output Kit v2,
loading 1.4 pM DNA and obtaining as cluster density an average of 200 K/mm2 clusters. Microarray
HumanCytoSNP for CNA analysis was performed by Genomix4life S.R.L. (Baronissi, Salerno, Italy),
using 200 ng of each DNA hybridized for 18 h at 48 ◦C on HumanCytoSNP-12 v2.1 BeadChip, according
to the manufacturer’s instructions, and analysed with an Illumina iSCAN. WES and SNP data analyses
were performed using the pipeline shown in Figure S1, using each patient’s germline DNA as reference.
The data generated or analysed during this study are included in this article, or if absent, are available
from the corresponding author upon reasonable request.
2.9. Pyrosequencing Analysis
The presence and allele frequency of TP53 and PIK3R1 mutations in source tumours of any PDX
line were assessed using pyrosequencing (QIAGEN, Hilden, Germany). Briefly, sample DNAs were
amplified, and the PCR products were subjected to the ‘sequence by synthesis’ pyrosequencing method
following the manufacturer’s instructions, using the primers and conditions reported in Table S5.
Results were analysed with the PSQ24 software for allelic quantification.
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3. Results
3.1. Mutational Burden of PDX Lines from HGS-EOCs
Forty-three PDX lines derived from epithelial ovarian carcinomas were fully characterized
according to the minimal information standard for reporting PDX data [22], including clinical and
pathological attributes of the patient’s tumour, the processes of implantation and passaging in the
host mouse strain, and quality assurance by means of genotypic and phenotypic characterization.
The information is reported in Table S1. Briefly, we compared the histology of each PDX to that of the
source tumour and classified histotype using immunohistochemistry (IHC) with CK7, EPCAM, WT1
and p53 antibodies, which confirmed the diagnosis of high grade serous histology in 25/43 lines. Figure 1
shows the histology and IHC staining of TMAs of representative PDX lines and the corresponding
source tumours. Targeted NGS of TP53 showed that all the PDXs from HGS-EOC harboured TP53
mutations (Table S1). TP53 aberrations were protein truncating or missense mutations previously
shown to be pathogenic according to the IARC TP53 Database (http://p53.iarc.fr/). The detailed list
of aberrations is reported in Table S1. Samples with missense mutations in TP53 had evidence of
nuclear p53 stabilization as indicated by high protein expression in tumours and xenografts (Table S1).
The PDX line with null splice site mutation did not express p53 protein. The targeted NGS of BRCA1/2
showed mutations of these genes classified as likely pathogenic according to the BRCA Mutation
Database (http://arup.utah.edu/database/BRCA) in 19% of the above PDX lines, i.e., close to the expected
frequency. The likely impactful aberrations and the variants of unknown significance detected in the
43 PDX lines are listed in Table S1.
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Figure 1. Histological characterization of PDX lines. Representative images of TMAs of PDX lines
compared to sections of the corresponding source tumours. Numbers on the left are those of PDX lines
as catalogued by the PROFILING approved protocol, while the numbers of the used FFPE block of
samples of source tumours are shown on the top left of each panel. The complete characterization of
these and the other thirty-eight PDX lines is reported in Table S1.
We then further studied 12 PDX lines propagated from treatment naïve HGS-EOCs, listed in
Table S2, that also reports clinical information.
In the 12 PDX lines, using Whole Exome Sequencing (WES), we detected a total of 2743 single
nucleotide variants (SNVs) in 2314 genes. The majority (79%) of mutated genes in our analysis have
been reported as mutated in the TCGA analysis of 523 HGS-EOC [8]. Most (438/487) of the mutated
genes not listed in the TCGA analyses of HGS-EOC have been found mutated in other cancer histotypes,
according to the Pan-Cancer Atlas.
TP53 was the only gene mutated in all 12 PDX lines, and the only gene found mutated across more
than one PDX line (Table S1), with an allele frequency of approximately = 1, in line with occurrence of
LOH. As expected, in the studied 12 PDX lines, WES detected the same TP53 mutations identified with
targeted NGS.
3.2. Somatic PIK3R1W624R Mutation in HGS-EOC
To identify possible driver and actionable genetic aberrations in the 12 above-mentioned PDX
lines, we considered SNVs and copy number alterations (CNAs) affecting cancer-related genes reported
in COSMIC (CGCv84) [28].
CNAs detected in cancer genes corresponded to those reported in TCGA for HGS-EOC (Table S3A).
Among genes reported in TCGA as amplified in more than 10% of cases [29], in our small series
(Table S3B) we found the expected frequency of increased copy number of CCNE1 and PIK3CA. LOH of
the TP53 gene in each of the PDX lines was confirmed (compare the data of Tables S1 and S2).
The list of cancer genes harbouring SNVs in the 12 PDX lines is shown in Figure 2 and Table S4.
It came out that, in 3/12 PDX lines, WES did not detect mutations in known cancer genes other
than TP53. A number of SNVs in cancer genes were identified as Single Nucleotide Polymorphisms
(SNPs). All the variants are listed in Table S4. Only some of the somatic mutations in the remaining 9
PDX lines were predicted to be damaging and/or deleterious based on the bioinformatics tools used
for analysis (Figure 2, SIFT, PROVEAN and FATHMM [30]). Possible actionability (Figure 2) was
evaluated using the Drug Gene interaction database (DGidb) [31].
In the PDX line #475, we found a point mutation of the PIK3R1 gene that results in the W624R
residue substitution in the encoded protein. This was detected with an allele frequency approximately
= 1.0, which suggested that this was a loss of function mutation followed by LOH, in accordance with
PIK3R1 classification as a tumour suppressor gene. As explained above, based on the bioinformatic
tools (see Figure 2), this mutation was predicted to be deleterious and damaging and possibly actionable.
PIK3R1 encodes the p85α regulatory subunit of the p110α catalytic subunit of the Phosphatidyl-Inositol-3
Kinase (PI3K). Some of the already known mutations of the p85α subunit affect the intracellular
signalling of the PI3K pathway, leading to PI3K activation, via distinct molecular mechanisms [32].
Activation of the PI3K pathway in this PDX line #475 was shown by the immunohistochemical detection
of the phosphorylation of the S6 protein, that is a proxy of AKT activation (Figure S2). In other PDX
lines, without mutations of genes involved in the PI3K/AKT/mTOR pathway, the P-S6 protein is not
comparably increased (Figure S2).
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line that came out to be limitedly effective. At post-chemotherapy surgery, another sample was
propagated as the PDX line, which no longer responded to carboplatin. In this paired PDX line the
PIK3R1W624R mutation was also found with an AF approximately = 1. More importantly, we found the
same PIK3R1W624R mutation in specimens of the source tumour. Pyrosequencing of two distinct FFPE
samples of the source tumour showed that in each FFPE sample the percentage of the PIK3R1W624R
sequence was the same as that of the TP53 allele found mutated in the PDX line (panels B–E of Figure 3).
The percentage of the mutated TP53 allele was considered a reliable proxy of the percentage of tumour
cells in the source tumour specimens.
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one of several public mutations found in seven parallel and serial passages of the PDX line#475.
(B–E) Pyrosequencing analysis confirmed the presence of the TP53 and the PIK3R1 mutations found
in the #475 PDX line in two FFPE samples from distinct blocks of the source tumour. The TP53 and
the PIK3R1 mutated sequences showed the same allele frequency (AF) in each sample. The AF of the
PDX line-specific TP53 mutation was considered as a proxy of the percentage of tumour cells in the
human tumour samples. (B) Sequence of PIK3R1 in Control Reference Genome; (C) percentage of
PIK3R1W624R in FFPE sample A1 from the paraffin block 2998 of the source tumour; (D) percentage of
PIK3R1W624R in FFPE sample A4 from the paraffin block 2304 of the source tumour; (E) percentage of
mutated sequences of TP53 and PIK3R1 in the two above FFPE samples.
3.3. Ex Vivo and In Vivo Assays of PIK3R1W624R Actionability
As mentioned above, to estimate the therapeutic implications of any given mutation, we first
used the Drug Gene interaction database (DGidb) [31] that suggested the actionability of PIK3R1W624R.
Another resource, the DEPO database (Database of Evidence for Precision Oncology, http://depo-
dinglab.ddns.net/), that focuses on specific mutations for therapeutic projections, was not useful
because it does not report hotspot regions of the PIK3R1 gene. However, we focused further attention
on this mutation because of the potential actionability of a member of the PI3K-AKT-mTOR pathway.
Hypothesis on the functional role of any given mutation can also be formulated based on crystal
structures of the molecules and complex of interest. Thus, we investigated the possible role of the
W624R mutation in the interaction between the p85 isoforms and p110 isoforms of PI3K (Figure 4).
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Figure 4. Crystal structures showing interaction of the p110 isoforms with the p85 isoforms in human
and mouse PI3K. (A) Domain organization of p85α. (B) Available crystal structure (PDB ID 4L1B)
of human p110α isoform with catalytic activity (grey) complexed with nSH2 (blue) and iSH2 (green)
domains of human p85α; (C) available crystal structure (PDB ID 2Y3A) of mouse p110β in complex
with iSH2 (green) a d cSH2 (pink) domains of mouse p85β. (D) Alig cS 2 domains of the
human p85α and mouse p85β; homology is shown i the mid le: the human p85α protein is
conserved and corresponds to the W616 of the mouse p85β protein (r in D).
Regrettably, only the crystal structure of hu an p110α in complex with nSH2 and iSH2 domains
of p85α is available (PDB ID 4L1B, Figure 4B). Hence, we explored the possible role of the amino-acid
residue homologue to the W624 in mouse p85 being available in the crystal structure of mouse p110β
isoform in complex with iSH2 and cSH2 domains of mouse p85β isoform (PDB ID 2Y3A, Figure 4C).
Structure superimposition showed that mouse p85β shares common folds with the human p85α
counterpart. Sequence alignments demonstrated that human p85α and mouse p85β display 73%
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homology and 59% identity, whereas human p110α and mouse p110β sequences have 57% homology
and 40% identity. According to sequence alignment (Figure 4D), the W624 in the human p85α
corresponds to W616 in the mouse cSH2 domain of p85β. These data analyses showed that the W616
in the cSH2 domain of mouse p85β is not involved in the interaction between murine p85β and p110β.
Thus, the structure-based prediction was inconclusive.
Thus, we carried out the functional assays (Figure 5) of the PIK3R1W624R in cells of the PIK3R1W624R
carrying PDX line #475 ex vivo, by challenging the susceptibility to inhibitors of the PI3K/AKT/mTOR
pathway that could be activated by suppression of the p85α regulatory subunit and fruitfully targeted
for therapy.
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Figure 5. Response of PIK3R1W624R carrying PDTCs to inhibitors of the PI3K/AKT/mTOR pathway.
In each experiment, control cell lines were assayed, too. (A,C,E,G): Dose-response curves in CellTiterGlo
72 h viability assays. Normalized growth rate (GR value) inhibition metrics of three replicate experiments
is shown to ake into account cell division rates. The sign of GR valu s relates dir ctly to response
phenotype: positive for partial growth inhibition, zero for complete cytostatic effect and negative for
cytotoxicity. The x axis shows drug concentration on a log10 (Log) scale. (B,D,F,H): Western blot analysis
of the phosphorylation of the AKT signal transducer in response to drugs, as a proxy of PI3K activation
status. (A) The PIK3R1W624R PDTCs showed susceptibility to the pan-class I PI3K inhibitor buparlisib
(BKM120), comparable to that of the highly responsive A2780 cells; (C) the PIK3R1W624R PDTCs showed
susceptibility to the dual PI3K/mTOR inhibitor dactolisib (BEZ235), comparable to th t of the most
sensitive (OVCAR-8) of the above c ll lines; (E) the PIK3R1W624R PDTCs were also highly susceptible
to the p110α specific PI3K inhibitor alpelisib (BYL719) as well as the A2780 cells; and (G) resistant to
the p110β specific inhibitor GSK2636771 to which the LNCaP cells are exquisitely susceptible.
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To test cell susceptibility to drugs ex vivo, we propagated the PDX Derived Tumour Cells (PDTCs)
depleted of mouse cells as short-term cultures. Viability assays were carried out by exposing PDTCs
to inhibitors for 72 h. The susceptibility of PIK3R1W624R PDTCs was compared to that of the control
cell lines (Figure 5) and to that of the PDTCs derived from the #2085 PDX line (Figure S3). The latter
PDTCs were propagated from a bona fide HGS-EOC, carrying mutations of the TP53 and BRCA2
genes (Table S1), but not of genes involved in the PI3K/AKT/mTOR pathway. The following cell
lines were assayed as controls, selected based on mutation spectrum (Cancer Cell Line Encyclopedia,
https://portals.broadinstitute.org/ccle) and susceptibility or resistance to any given drug: A2780 ovarian
carcinoma cells, carrying PIK3CA activating mutation and PTEN loss that make them highly sensitive
to the pan-class I PI3K inhibitor buparlisib (BKM120), to the p110α specific inhibitor alpelisib (BYL-719)
and to the dual PI3K/mTOR inhibitor dactolisib (BEZ235); the OVCAR-8 ovarian carcinoma cells with
wild-type PIK3CA and TP53 gene mutation, but known to be susceptible to the dual PI3K/mTOR
inhibitor dactolisib (BEZ235), as reported by the Genomic of Drug Sensitivity in Cancer Project
(https://www.cancerrxgene.org/), and the PTEN-mutated LNCaP prostate carcinoma cells that are
known to be exquisitely susceptible to the p110β specific inhibitor GSK2636771. To take into account
cell division rates across the PDTCs and cell lines, growth rate inhibition metrics were used, i.e.,
GR-calculator [27].
The PIK3R1W624R #475 PDTCs but not the non-mutated #2085 PDTCs, were sensitive to the
pan-class I PI3K inhibitor buparlisib (BKM120) as shown in Figure 5 and Figure S3, respectively.
Figure 5 also shows the susceptibility of the PIK3R1W624R #475 PDTCs to the p110α specific inhibitor
alpelisib (BYL-719), compared to control cell lines. Similarly, these #475 PDTCs showed susceptibility
to the dual PI3K and mTOR inhibitors dactolisib (BEZ235). Conversely, the p110β selective inhibitor
GSK2636771 did not affect the PIK3R1W624R PDTCs. The susceptibility of PIK3R1W624R PDTCs to
the four inhibitors was confirmed with a cytotoxicity assay (Figure S4). In line with the results of
viability assays, buparlisib, dactolisib and alpelisib, but not GSK2636771, affected AKT phosphorylation
(Figure 5), that is a proxy of PI3K activation status.
Moreover, in vivo buparlisib delayed the growth of the PIK3R1W624R PDXs (Figure 6A). As the
total decrease of tumour volume could not allow proper estimation of possibly cytostatic agents,
we demonstrated also the strong reduction of Ki67 positive, i.e., proliferating, cells in treated PDXs
(Figure 7A,C). AKT phosphorylation was reduced in xenografts in line with growth delay by buparlisib
treatment (Figure 6B). Accordingly, phosphorylation of the S6 protein, that is a proxy of the PI3K/AKT
activation, was reduced (Figure 7B,D).
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4. Discussion
We demonstrate here that a rare mutation in the PIK3R1 tumour suppressor gene [29] is actionable
in HGS-EOC using validated patient-derived models of the disease. PIK3R1 is very frequently mutated
in other cancer histotypes, with the notable exception of HGS-EOC [10], in particular in uterine
carcinomas and carcinosarcomas, glioblastoma, breast and colorectal cancer. Most of the mutations
reported so far are located in the iSH2 domain of the PIK3R1 encoded p85α, which is known to bind
and regulate the p110α subunit of PI3K [32]. The PIK3R1W624R mutation described here is located in
the cSH2 domain of the p85α. The same W624R amino acid change has been reported previously,
but not characterized, in one colorectal cancer [34], while a W624C substitution has been reported
in one non-small cell lung carcinoma (NSCLC) [35], and a nucleotide change in the same codon,
leading to a non-sense mutation being found in one stomach cancer sample [36] and one endometrial
carcinoma [37]. Other rare mutations in the cSH2 of the PIK3R1 gene are reported in COSMIC
(https://cancer.sanger.ac.uk/cosmic) and TumorPortal (http://www.tumorportal.org). The function
of a number of these mutations has been studied in test tubes (see e.g., ref. [38]) or in functional
assays in cell line models with totally different genetic backgrounds (see e.g., refs. [39,40]). As a result,
the potential oncogenicity of only two mutations in the p85α cSH2 domain has been proposed based
on the promotion of survival and growth of Ba/F3, a murine interleukin-3 dependent pro-B cell line.
On the other hand, in the cSH2 domain of the p85α, several germline mutations are located, which in
heterozygosity cause SHORT syndrome [41]. This syndrome is characterised by developmental defects
and is historically defined by its acronym: Short stature (S), Hyperextensibility of joints and/or inguinal
Hernia (H), Ocular depression (O), Rieger abnormality (R) and Teething delay (T). Molecular studies
have shown that PIK3R1 mutations associated with SHORT syndrome result in defects, and not in the
activation of PI3K signalling [41,42].
Surprisingly, another mutation in the cSH2 domain (the R649W substitution) has been reported
in both endometrial carcinoma and as a hotspot in four families affected by SHORT syndrome [42].
Therefore, although prediction algorithms allowed us to classify the W624R amino acid change in
PIK3R1 as possibly deleterious and damaging the protein product, it was difficult to predict its actual
impact on ovarian cancer. As structure-based approaches are more specific than sequence-based
approaches at predicting driver mutations [40], we endeavoured to model the association in p85α
between the W624R mutation and the p110α subunit, but available crystal structures did not help in
defining the impact of the PIK3R1W624R on human PI3K function. It has also been postulated that the
role of the cSH2 domain of the human p85α in oncogenesis relies on its interaction with and inhibition
of the p110β isoform of the PI3K [43]. We disproved this hypothesis with functional assays ex vivo
that showed directly the susceptibility in vitro of PIK3R1W624R PTDCs to the p110α specific inhibitor
alpelisib but not to the p110β specific inhibitor. Susceptibility to pathway inhibition was confirmed by
treating PDTCs with a dual PI3K/mTOR inhibitor and with the pan class I PI3K inhibitor buparlisib,
which also inhibited the growth of PDXs in vivo. These data confirmed the requirement of proper
functional assays for evaluating the driving oncogenic effect of any given mutation.
Other observations suggest that the impact of any mutation as well as its actionability could be
better studied in patient-derived models and in the actual tissue affected. Nowadays, the traditional
system of anatomic cancer classification has been overcome by a classification system based on
molecular alterations shared by tumours across diverse tissue types. This concept has led to the
development of so-called basket or umbrella trials. However, exceptions that challenge this concept
have also become apparent from such notable examples as the unpredictable clinical responses to a
potent BRAF inhibitor across diverse malignancies, all expressing the same BRAF mutation [44].
Altogether, the data show that, to assess the function of mutant alleles, assays in patient-derived
models of the relevant cancer, such as PDXs and short-term PDTCs, are extremely important. Long-term
cultures of patients’ samples [45] are useful for drug screening. Short-term monolayer cultures [46]
and organoids [47] derived from patients’ biopsies have been shown as a valuable model for rapid
drug testing and thus for co-clinical trials, but their application may be limited by the modest take and
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throughput, respectively. Thus, all the patient-derived experimental models should be considered
complementary and not alternative, as every model system is imperfect and suitable in its own way.
The validation of PIK3R1W624R as a biomarker of response to PI3K/AKT/mTOR pathway inhibitors
exceeds the aim of this work. The PI3K-AKT-mTOR signalling pathway is one of the most frequently
dysregulated ones in human cancers. More than 40 inhibitors of this pathway have reached
various stages of clinical development, but only a few have been approved by FDA and EMA [48].
In clinical studies, inhibitors of the pathway have shown limited efficacy and/or manageability [20].
P110 isoform-specific inhibitors appear more promising in trials [49–51]. In ovarian cancer, gene
abnormalities other than homologous recombination defects are even more difficult to pair with an
approved or investigational drug [52].
5. Conclusions
In the ovarian cancer field, suitable preclinical models such as PDXs are still invaluable for
population-based studies, as they might better mimic the inter-tumour heterogeneity that is seen in
patients and might be predictive of the clinical efficacy of targeted drugs. This model allowed us
to identify a rare mutation in the PIK3R1 gene in a domain that was not expected to be involved in
oncogenesis, and showing that this mutation makes ovarian cancer cells responsive to inhibitors of the
PI3K/AKT/mTOR pathway.
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